Business Description
Ocular Therapeutix is a US-based company focused on treating eye diseases through its proprietary dissolvable gel technology. Its flagship product, DEXTENZA, is already on the market and helps manage eye inflammation, pain, and allergic reactions. The company is also advancing a pipeline of next-generation treatments for serious conditions such as macular degeneration, diabetic eye disease, and glaucoma, with several programs in late-stage clinical testing. Founded in 2006 and based in Bedford, Massachusetts, Ocular Therapeutix works with partner AffaMed Therapeutics to expand the reach of select products into additional markets.
